Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib

With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.